We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Angle plc (AGL) Ordinary 10p

Sell:9.00p Buy:10.00p 0 Change: 0.25p (2.56%)
Market closed |  Prices as at close on 2 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.00p
Buy:10.00p
Change: 0.25p (2.56%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 2 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.00p
Buy:10.00p
Change: 0.25p (2.56%)
Market closed |  Prices as at close on 2 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Angle completes assay development projects

    21 March 2025 11:05

    (Sharecast News) - Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further expanding its portfolio of liquid biopsy solutions and strengthening...

  • Angle's Parsortix system used in 'breakthrough' breast cancer research

    24 January 2025 10:51

    (Sharecast News) - Liquid biopsy specialist Angle announced on Friday that its Parsortix system played a pivotal role in groundbreaking breast cancer research published in Nature Medicine by a team led by...

  • Berenberg slashes target price on Angle

    23 January 2025 11:21

    (Sharecast News) - Analysts at Berenberg slashed their target price on liquid biopsy specialist Angle from 70.0p to 40.0p on Thursday but said the group was "repositioned for growth" in FY25.

  • Angle signs new agreement US biotech Recursion

    19 September 2024 12:40

    (Sharecast News) - Angle's share price received a boost on Thursday after the liquid biopsy company announced a new agreement with Utah-based biotech firm Recursion Pharmaceuticals.

  • Angle unveils plans to raise more than £10m

    5 June 2024 10:08

    (Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

  • Angle reports promising results from Parsortix study

    16 May 2024 11:46

    (Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system...

  • Angle strikes supplier deal with AstraZeneca

    3 May 2024 07:58

    (Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

  • Angle granted European patent for CellKeep, US patent imminent

    22 April 2024 06:59

    (Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US...

  • Angle receives 'breakthrough results' from DNA molecular analysis

    4 January 2024 07:58

    (Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

  • Angle locks in $250,000 contract with Eisai

    2 January 2024 09:04

    (Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

  • Angle losses widen in 'breakthrough year'

    21 April 2023 11:06

    (Sharecast News) - Liquid biopsy specialist Angle described a "breakthrough year" in its 2022 results on Friday, with both FDA clearance and positive results from the ovarian cancer study being...

  • Tougher market conditions impacting Angle clients

    5 January 2023 16:09

    (Sharecast News) - Liquid biopsy specialist Angle said in an update on Thursday that actions taken to control its cost base, and the closure of its Canadian operations, left it on track to deliver expected...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2025. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.